Overview
The linked papers investigate LL-37 in bacterial and immune-cell experiments. The reported laboratory concentrations and biofilm findings are presented as laboratory evidence.[1][2] Laboratory exposure is not a clinical dosing schedule. These experiments do not establish a treatment benefit or a human administration regimen.[1][2] The sections below distinguish measured findings from broader benefit claims and identify the information needed to interpret formulation, timing, and safety. A result remains attached to the population and intervention in which it was observed.
Benefits
This guide links 2 study records for LL-37, but the presence of records is not itself an assessment of clinical benefit. A useful benefit claim needs an identifiable outcome, an appropriate comparison, and a description of who or what was studied. Laboratory activity, a biomarker response, and an improvement in symptoms should be assessed separately. Until the relevant results and limitations have been evaluated, this guide does not assign an effectiveness grade or translate a proposed use into an established benefit.
Safety
This LL-37 guide does not yet provide a complete clinical safety assessment for a specific formulation and use. Such an assessment would need the exposure, route, participant characteristics, adverse events, and duration of follow-up from the relevant primary studies. Missing safety information cannot be interpreted as an absence of risk, and a reported event needs context before causation is assigned. Findings from one setting should remain separate from claims about another product, population, or combination.
Contraindications
The evidence summarized on this LL-37 page is not sufficient to construct a complete contraindication list for clinical use. A study’s inclusion and exclusion criteria describe its selected participants, but they do not determine suitability for everyone outside that study. Interpreting a potential contraindication requires the exact product, intended use, health condition, and supporting evidence. This section therefore leaves unanswered suitability questions explicit instead of turning unstudied circumstances into either permission or a categorical clinical rule.
Interactions
This guide does not establish an interaction profile for LL-37 with other peptides, medicines, or supplements. To evaluate a particular combination, the relevant evidence would need to identify the coadministered substances, formulation, route, and measured effects. Results for ingredients studied separately cannot determine whether combining them changes benefit, exposure, or harm. Related stack pages distinguish those ingredient findings from direct combination evidence and keep any unresolved interaction questions visible.
Forms & dosing
A validated dosing recommendation for LL-37 cannot be inferred from the material currently summarized in this guide. When study records report an amount or concentration, that value belongs to the specific preparation, route, schedule, and experimental setting described in the source. Laboratory concentrations and human treatment regimens should remain separately identified. This page will not convert an isolated reported number into a consumer dose, a cycle, or a protocol for a different formulation or combination.
Results & stopping
This LL-37 guide does not establish a general time to benefit or what happens after treatment stops. Those questions require a defined outcome, repeated measurements, and follow-up that extends beyond the intervention when persistence is being assessed. A pharmacological response during exposure would answer a different question from a sustained improvement in symptoms or function. Any future timeline should therefore state exactly what changed, when it was measured, and whether the study actually observed participants after discontinuation.
Product quality
The studies attached to a topic do not, by themselves, validate the quality of a commercial LL-37 product. Evaluating a particular preparation requires information about its identity, composition, batch, and intended route, with testing appropriate to the claim being made. A supplier’s label cannot establish that the contents match a research intervention. This guide keeps product characterization separate from clinical effectiveness and does not endorse a vendor or finished product on the basis of an ingredient study.
Status
This page does not provide a verified, product-specific regulatory determination for LL-37. Approval, research use, and availability need to be distinguished for the exact preparation, indication, and jurisdiction being considered. A publication establishes that an experiment was reported; it does not by itself establish authorization to market a product. Regulatory conclusions should be added only with a dated primary agency source, while research findings remain tied to the intervention actually investigated.
Evidence
These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.
| Outcome, finding and study design | Evidence certainty | Sources |
|---|---|---|
No outcome assessment is available for this guide yet. Source records below have not been synthesized into an assessment of benefit or safety. Inspect the available research | ||
Research Feed
Studies
Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.
Efficacy of LL‑37 cream in enhancing healing of diabetic foot ulcer: a randomized double‑blind controlled trial
Discovery of novel antibacterial agent for the infected wound treatment: all-hydrocarbon stapling optimization of LL-37
Role of LL‑37 in thrombotic complications in patients with COVID‑19
Influence of Lipidation Pattern of the KR12 Fragment of Peptide LL-37 on Its Antibacterial and Hemolytic Activities
Self-assembly of PEG–PPS polymers and LL-37 peptide nanomicelles improves the oxidative microenvironment and promotes angiogenesis to facilitate chronic wound healing
LL-37-Coupled Porous Composite Scaffold for the Treatment of Infected Segmental Bone Defect
LL‑37 regulates odontogenic differentiation of dental pulp stem cells in an inflammatory microenvironment
Interactions of Laurylated and Myristoylated KR12 Fragment of the LL37 Peptide with Polyoxidovanadates
Glioblastoma Multiforme: Sensitivity to Antimicrobial Peptides LL-37 and PG-1, and Their Combination with Chemotherapy for Predicting the Overall Survival of Patients
Anticandidal Activity of Lipopeptides Containing an LL-37-Derived Peptide Fragment KR12
Assessment of Antimicrobial Activity of LL‑37 Peptide Against Periapical Pathogens: A Cross‑Sectional Study
Genetically Modified Mesenchymal Stromal/Stem Cells as a Delivery Platform for SE-33, a Cathelicidin LL-37 Analogue: Preclinical Pharmacokinetics and Tissue Distribution in C57BL/6 Mice
Synthesis and evaluation of KR-12, an LL-37 fragment, and its shortchain fatty acid derivatives: selective cytotoxicity in colorectal cancer cells and anti-tumor efficacy in an azoxymethane/DSS-induced colitisassociated cancer mouse model
Development and Characterization of LL37 Antimicrobial-Peptide-Loaded Chitosan Nanoparticles: An Antimicrobial Sustained Release System
Suramin blocked hCAP18/LL-37-induced macrophage recruitment and M2 polarization to enhance the therapeutic efficacy of 1,25(OH)2D3 against hepatocellular carcinoma in vitro and in vivo mouse model
Plasma levels of antimicrobial peptide LL-37 as a biomarker of sleep quality in patients with obstructive sleep apnea: A clinical observational study
LL-37 IgG levels are associated with clinical characteristics and T follicular cell response in acute coronary syndrome in adults
Comparing the genetic and serum expression of LL-37 Antimicrobial Peptide in pemphigus vulgaris and pemphigus foliaceus patients
Interaction between vitamin D insufficiency and periodontitis, GCF vitamin D and LL-37 levels in well-controlled diabetes patients with periodontitis
FAQs
What can this guide currently establish about LL-37?
This guide links 2 study records for LL-37, but the presence of records is not itself an assessment of clinical benefit. A useful benefit claim needs an identifiable outcome, an appropriate comparison, and a description of who or what was studied. Laboratory activity, a biomarker response, and an improvement in symptoms should be assessed separately. Until the relevant results and limitations have been evaluated, this guide does not assign an effectiveness grade or translate a proposed use into an established benefit.
Do reported study amounts establish a dosing recommendation?
A validated dosing recommendation for LL-37 cannot be inferred from the material currently summarized in this guide. When study records report an amount or concentration, that value belongs to the specific preparation, route, schedule, and experimental setting described in the source. Laboratory concentrations and human treatment regimens should remain separately identified. This page will not convert an isolated reported number into a consumer dose, a cycle, or a protocol for a different formulation or combination.
Update History
Evidence and review status
- Recorded source check
- Subsequent substantive evidence update
- No later update is recorded for LL-37.
- Independent clinical review
- Pending; this selected-source guide is AI-assisted.
A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.
Read the editorial methodReferences
2 sources
- Uropathogenic_Escherichia_coli_modulates_immune_responses_and_its_curli__20661475_PMC2908543.pdf (Accessed 2026-10-04)Primary research · See study record for population and routeReview status · PendingSave study
- Self_RNA_antimicrobial_peptide_complexes_activate_human_dendritic_cells__19703986_PMC2737167.pdf (Accessed 2026-10-04)Primary research · See study record for population and routeReview status · PendingSave study
